-
Professor Wasilijiang·Wahafu: Targeted Therapy Plus Immunotherapy Redefines Advanced Urothelial Carcinoma Care with Multidisciplinary Support
Editor’s Note: Advanced urothelial carcinoma is a highly aggressive malignancy associated with poor prognosis, posing a serious threat to patient survival and quality of life. In recent years, continuous breakthroughs…
-
Professor Kohei Shitara: Advancing Immunotherapy in Gastrointestinal Cancers—Cancer Vaccines, T-Cell Engagers, and Other Emerging Strategies May Lead the Next Wave
Immunotherapy has fundamentally reshaped the treatment landscape of gastrointestinal (GI) cancers. However, now that PD-1/PD-L1 inhibitors have been firmly established as standards of care, the key challenge facing clinical research is how to further overcome the current efficacy plateau. This has driven research into a “deep-water zone,” where novel strategies—such as next-generation TIGIT inhibitors, cancer…
-
On-site from ESMO Asia | Professor Liangyou Gu: Disitamab Vedotin Plus Immunotherapy Brings New Hope for Adjuvant Treatment of UTUC
1. Challenges of Adjuvant Therapy in Locally Advanced UTUC Compared with bladder cancer, UTUC is more aggressive and associated with poorer outcomes. Even after radical surgery, the 5-year disease-free survival…
-
Professor Peng Zhang: The HOPE Program Paves the Way for Bladder-Preserving Care in Urothelial Carcinoma
Oncology Frontier – UroStream: The West China urology team has accumulated extensive experience in urothelial carcinoma. In the exploration of ADC-based neoadjuvant/adjuvant therapy and organ-preserving strategies, what key clinical studies…
-
ASH China Voice | Professors Lu Peihua / Zhang Xian: CD7 CAR-T Therapy Significantly Improves Outcomes in R/R CD7-Positive Hematologic Malignancies
Title CD7 CAR-T Cell Therapy Based on “Natural Selection” for the Treatment of Relapsed or Refractory CD7-Positive Hematologic Malignancies: A Large Cohort Study Chinese Title 基于“自然选择”平台的CD7 CAR-T细胞治疗复发/难治性CD7阳性血液系统恶性肿瘤：一项大样本队列研究 First Author Zhang…
-
ASH Hot Topics | Prof. Yang Linhua: Anti-BAFF-R mAb Advances ITP from Symptom Control to Disease Modification
Immune thrombocytopenia (ITP) is an immune-mediated thrombocytopenic disorder that can lead to severe bleeding and markedly impair quality of life. At the 67th Annual Meeting of the American Society of…
-
ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China
On December 6 (local time), a highly anticipated special session on the ASH Clinical Practice Guidelines on Myelofibrosis was successfully held during the American Society of Hematology (ASH) Annual Meeting.…
-
ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international…
Connecting Medical Expertise through Media